(Q35929973)

11 August 2017

1 reference

title

Practical guidelines to interpret plasma concentrations of antiretroviral drugs. (English)

1 reference

11 August 2017

anti-retroviral agent

0 references

6

Jos H Beijnen

1 reference

11 August 2017

5

Alwin D R Huitema

1 reference

11 August 2017

Bregt S Kappelhoff

1

1 reference

11 August 2017

Kristel M L Crommentuyn

series ordinal

2

1 reference

11 August 2017

Monique M R de Maat

series ordinal

3

1 reference

11 August 2017

Jan W Mulder

series ordinal

4

1 reference

11 August 2017

1 January 2004

1 reference

Clinical Pharmacokinetics

11 August 2017

1 reference

11 August 2017

43

1 reference

11 August 2017

13

1 reference

11 August 2017

845-853

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200443130-00002

11 August 2017

0 references

cites work

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

1 reference

12 December 2020

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir

1 reference

12 December 2020

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

1 reference

12 December 2020

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

1 reference

12 December 2020

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

1 reference

12 December 2020

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

12 December 2020

Incidence and risk factors for nevirapine-associated rash

1 reference

12 December 2020

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

1 reference

12 December 2020

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

1 reference

12 December 2020

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

1 reference

12 December 2020

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

1 reference

12 December 2020

Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs

1 reference

12 December 2020

Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART.

1 reference

12 December 2020

Principles and practice of HIV-protease inhibitor pharmacoenhancement

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Management of sudden psychiatric disorders related to efavirenz

1 reference

12 December 2020

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study

1 reference

12 December 2020

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

1 reference

12 December 2020

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial

1 reference

12 December 2020

High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen

1 reference

12 December 2020

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

12 December 2020

Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.

1 reference

12 December 2020

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).

1 reference

12 December 2020

Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy

1 reference

12 December 2020

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection

1 reference

12 December 2020

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

12 December 2020

Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals

1 reference

12 December 2020

Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?

1 reference

12 December 2020

Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children

1 reference

12 December 2020

Liver toxicity caused by nevirapine

1 reference

12 December 2020

Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection.

1 reference

12 December 2020

Higher efavirenz plasma levels correlate with development of insomnia

1 reference

12 December 2020

Drug interactions between antiretroviral drugs and comedicated agents

1 reference

12 December 2020

Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios

1 reference

12 December 2020

Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance

1 reference

12 December 2020

Indinavir concentrations and antiviral effect

1 reference

12 December 2020

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

12 December 2020

CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid

1 reference

12 December 2020

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

12 December 2020

Position paper on therapeutic drug monitoring of antiretroviral agents

1 reference

12 December 2020

Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients

1 reference

12 December 2020

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Low-dose ritonavir moderately enhances nelfinavir exposure

1 reference

12 December 2020

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population

1 reference

12 December 2020

10.2165/00003088-200443130-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference